Single CRISPR infusion cuts stubborn LDL cholesterol for a year
A single dose of CTX310, a CRISPR-Cas9 therapy, dropped LDL cholesterol by more than half in patients who did not respond to standard drugs. The effect lasted at least a year.
Biotech Signals 43 articles
Precure LLC and Helix launch million-sample multiomics push at Mayo Clinic
Precure LLC has picked Helix to handle clinical whole genome and multiomics data from a million biospecimens. This marks a major step for precision medicine at Mayo Clinic and could reshape care across health systems.
Regulatory hurdles put City of Hope's PANXEON pancreatic cancer test to the test
City of Hope's PANXEON liquid biopsy shows 87 percent sensitivity for early pancreatic cancer. Now, tough regulatory and reimbursement questions could decide if it ever reaches patients.
Genomic mapping unlocks new insights into threatened Asian hornbills
A breakthrough in hornbill genomics offers scientists new tools to trace species history and guide conservation of four threatened Asian hornbills.
Phase III trial data volumes double every seven years as complexity becomes the new normal
Phase III clinical trials now generate 5.9 million data points per protocol on average, with data volumes rising 11 percent annually since 2020 and operational models straining to keep pace.
Australian government funds international CAR-T clinical trials for children
A new five million dollar grant from the Australian Government will bring international CAR-T clinical trials for childhood cancer to Australia, reducing the need for families to seek treatment overseas.
Uzbekistan plans Biome center for cell technologies and genomics
Uzbekistan is moving ahead with a Biome center dedicated to cell technologies, genomics, and biobanking, aiming to strengthen its position in advanced bioscience research.
Sidra Medicine develops genomic tool to predict risk of cognitive decline
Researchers at Sidra Medicine have created a genomic method that combines genetic and brain imaging data to improve early prediction of cognitive decline, paving the way for more tailored brain health strategies.
Gene editing strategies take center stage in malaria research at MDU
MDU's Centre for Biotechnology brought leading scientists to campus to dissect how gene editing tools like CRISPR-Cas9 are reshaping malaria research and student training.
AI-designed genome editors offer new options for rice gene editing
Researchers at ICAR-Central Rice Research Institute have shown that Plant OpenCRISPR-1, an AI-designed genome editor, works as well as established systems for editing rice genes.
BriaCell Therapeutics advances off-the-shelf cancer immunotherapy into late-stage clinical trials
BriaCell Therapeutics is moving forward with off-the-shelf whole cell immunotherapies for late-stage cancers, with pivotal trials underway and new FDA clearance for prostate cancer.
Cardinal Health targets double-digit earnings growth as specialty business expands
Cardinal Health is aiming for 13 to 15 percent adjusted EPS growth in fiscal 2027, driven by momentum in its specialty segment and investments in oncology, urology, and autoimmune care.
AI patient profiling challenges the meaning of failed clinical trials
A failed Phase 3 trial does not always mean a drug is ineffective. Luca Pani of NetraMark argues that AI-driven patient selection could transform how clinical evidence is generated and interpreted.
AbbVie pursues dual antibody strategy to reshape lung cancer treatment
AbbVie is betting on a multimodal approach in lung cancer by combining bispecific antibodies with antibody-drug conjugates, aiming to overcome resistance and improve patient outcomes as new clinical data emerges.
Ireland’s cell therapy sector depends on imports as demand for activation beads rises
Ireland’s cell therapy industry is growing quickly, but nearly all detachable activation beads are imported. Rising GMP-grade demand and new allogeneic therapies are reshaping the market, but supply chain risks persist.
UK and Israel pursue new science and tech partnerships despite political tensions
British Ambassador Simon Walters is working to connect Israel with the Oxford-Cambridge Growth Corridor, aiming to build new partnerships in genomics, agri-tech, AI, and clean tech, even as political disagreements continue.
CAR-T therapy transforms relapsed lymphoma into a race for treatment access
CAR-T therapy offers a lifeline for patients with relapsed blood cancers, but the real challenge is getting the treatment before time and logistics run out.
Gujarat Themis Biosyn completes Rs 1,200 crore acquisition of MicroBiopharm Japan
Gujarat Themis Biosyn Limited has closed its Rs 1,200 crore deal to acquire MicroBiopharm Japan, gaining new biologics capabilities and a direct presence in regulated global markets.
Latus Bio brings on new board leaders as gene therapy trials approach
Latus Bio has named Donald Hayden as chairman and Michael MacLean as independent director, strengthening its board as the company prepares to start clinical trials for gene therapies targeting CLN2 disease and Huntington’s disease.
Lōkahi Therapeutics extends partnership with University of Alabama for hands-on biotech asset scouting
Lōkahi Therapeutics is strengthening its collaboration with The University of Alabama’s Culverhouse College of Business, giving students direct experience in evaluating real biopharma assets through the ai² Pipeline division.
AI designs new viruses to fight bacteria and rewrites the rules of biotechnology
Artificial intelligence has crossed a threshold in biotechnology by designing functional viruses that target bacteria, opening vast opportunities and urgent responsibilities for India and the world.
Bristol Myers Squibb's arlo-cel meets phase II goal in relapsed multiple myeloma
Bristol Myers Squibb reports that its phase II QUINTESSENTIAL trial of arlocabtagene autoleucel met the main goal in adults with relapsed and refractory multiple myeloma.
Gene edited rice faces backlash as coalition demands urgent policy reversal in India
A coalition of scientists and farmers is urging the Indian government to stop gene edited rice, warning of health, environmental, and economic risks, and calling for a return to Dr Richharia’s sustainable approach to agriculture.
Early decisions in cell and gene therapy shape patient access for years
Many cell and gene therapies remain out of reach for patients long after FDA approval. The real barriers are built years earlier, in the choices made around manufacturing, trial design, and regulatory strategy.
Genomics-driven translocation sparks early breeding surge in Florida scrub-jays
A bold genetic rescue experiment led by UCF biologist Lauren Deaner has triggered unprecedented early breeding among translocated Florida scrub-jays, offering new hope for species recovery.
Bristol Myers Squibb ends development of Orum Therapeutics' ORM-6151 after early trial review
Bristol Myers Squibb has stopped work on ORM-6151, a degrader-antibody conjugate from Orum Therapeutics, after reviewing Phase I trial data.
Andrew Dauber honored for advances in pediatric endocrinology research
Andrew Dauber, chief of Endocrinology at Children’s National, received the ESPE International Research Award in Marseille for his work on genetic growth disorders and precision medicine.
AI agents push into science as safety concerns and funding surge
OpenAI claims a breakthrough on a Millennium Prize problem as billions flow into AI and researchers warn about the risks of runaway systems. Genomics projects show AI’s potential for medicine, even as the industry faces tough questions about safety and oversight.
BioCytics partners with Eremid for single-cell sequencing in cancer cell therapy
BioCytics has brought in Eremid Genomic Services to run advanced single-cell transcriptomic and TCR sequencing on immune cells, aiming to speed up development of its autologous adaptive immune cell therapy for solid tumors.
Stanford deploys 37,000 AI agents to speed up drug discovery
Stanford researchers built a virtual biotech company powered by 37,000 AI agents, which quickly identified promising drug targets and independently suggested a cancer therapy later validated by a major pharmaceutical company.